



SAFETY DATA SHEET

Title: MAXALAC L.C. INTRAMAMMARY ANTIBIOTIC		Document: SDS-AU053	
		Rev: 1.0	Page: 1 of 7
Status: Current	Issue Date 24-Aug-2019	Effective Date: 24-Aug-2019	Review Date: 02-Jan-2023

Section 1: IDENTIFICATION of CHEMICAL PRODUCT and COMPANY

Product Name:	Maxalac L.C. Intramammary Antibiotic
Product Identifier:	92.2 g/kg cefuroxime sodium intramammary paste.
Product Code:	503205 (20 x 3 g syringes)
Recommended Use:	An intramammary infusion to treat mastitis in lactating cows.
Restrictions on Use:	For animal treatment only.
Company Identification:	Avet Health Pty Ltd
Address:	Unit F24, 16 Mars Road, Lane Cove, NSW 2066, Australia.
Customer Centre:	1300 28 38 28
Email:	info@avet.health
National Poisons Information Centre:	13 11 26 (24 hours)
Emergency Telephone Number:	1300 28 38 28 (9am – 5pm, Monday to Friday)

Section 2: HAZARDS IDENTIFICATION

GHS Hazard Classifications: This product has been assessed according to GHS and is classified as follows:

GHS Category	Hazard code	Hazard Statement
Skin sensitizer Category 1	H317	May cause an allergic skin reaction

GHS Label Elements:

Signal Word: **WARNING**

Pictograms:



Exclamation Mark

Precautionary Statements: Prevention



SAFETY DATA SHEET

Title: MAXALAC L.C. INTRAMAMMARY ANTIBIOTIC		Document: SDS-AU053	
		Rev: 1.0	Page: 1 of 7
Status: Current	Issue Date 24-Aug-2019	Effective Date: 24-Aug-2019	Review Date: 02-Jan-2023

P261 Avoid breathing vapours.
P272 Contaminated work clothing should not be allowed out of the workplace.
P280 Wear protective gloves.

Response

P320+P352 IF ON SKIN: Wash with plenty of water.
P333+P313 If skin irritation or rash occurs: Get medical advice/attention.
P362+P364 Take off contaminated clothing and wash it before reuse.

Storage

No storage statements.

Disposal

P501 Dispose of container and any unused product by wrapping with paper and putting in garbage.

N.B.: The above statements are determined by Work Health and Safety regulations and may not reflect Signal Headings and First Aid and Safety statements on product labelling, which are determined by a competent authority during assessment for registration.

Other hazards: Slippery when spilt.

Section 3: COMPOSITION / INFORMATION on INGREDIENTS

INGREDIENT	CAS No.	CONTENT
Cefuroxime sodium	56238-63-2	9.2%
Ingredients not contributing to the hazards	-	> 90%

Section 4: FIRST AID MEASURES

General Information: Consult the National Poisons Centre on 13 1126 or a doctor immediately in every case of suspected chemical poisoning. Never give fluids or induce vomiting if a patient is unconscious or convulsing regardless of cause of injury. If medical advice/attention is needed, have this SDS, product container or label at hand.

Symptoms and Effects of Exposure: None known.

Inhalation: If respiratory symptoms occur, remove patient to fresh air. Lay patient down and keep warm and rested. If breathing is shallow or has stopped, ensure airway is clear and apply resuscitation. If breathing is difficult, give oxygen. Seek medical assistance immediately.

Ingestion: If swallowed, DO NOT induce vomiting. Rinse mouth. Keep subject warm and at rest. For advice, contact a doctor or the National Poisons Centre on 13 1126.

Skin: If skin contact occurs, wash affected area thoroughly with plenty of soap and water for at least 20 minutes. If skin irritation or rash occurs, get medical advice/attention.

Eye: If eye contact occurs, rinse cautiously with water for at least 20 minutes. Continue rinsing. Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. If eye irritation persists, get medical advice/attention.



SAFETY DATA SHEET

Title: MAXALAC L.C. INTRAMAMMARY ANTIBIOTIC		Document: SDS-AU053	
		Rev: 1.0	Page: 1 of 7
Status: Current	Issue Date 24-Aug-2019	Effective Date: 24-Aug-2019	Review Date: 02-Jan-2023

Recommended First Aid Facilities: Ready access to running water and soap is required. Accessible eyewash is required.

Advice to Doctor: Treat as an overdose or sensitivity to cephalosporin antibiotics.

Section 5: FIRE FIGHTING MEASURES

Flash Point: No data available on the mixture. Flashpoint for peanut oil is 316°C (open).

Hazardous Combustion Products: If involved in a fire may emit toxic and corrosive fumes.

Extinguishing Media: There is no restriction on the type of extinguisher which may be used. Use extinguishing media suitable for surrounding area.

Protective Equipment: Protective gloves and boots and breathing apparatus.

Hazchem Code: None specified.

Section 6: ACCIDENTAL RELEASE MEASURES

Spills and Disposal: Slippery when spilt. Wear appropriate protective clothing. For small spills, wash area well with excess water. For large spills, exclude non-essential people from the area. Contain spill and absorb with inert material such as soil, sand or absorbent granules and place in a sealable waste container. Ventilate area and wash spill site after pick-up complete. Dispose of waste safely in an approved landfill.

Protective Clothing: For appropriate personal protective equipment see section 8.

Environmental Precautions: Prevent from entering drains, waterways or sewers. If contamination of drains and waterways occurs, advise local authority.

Section 7: HANDLING AND STORAGE

Handling: The product should be handled with care to avoid exposure. Avoid contact with skin, eyes and inhalation of vapours. Use personal protective equipment as required. Do not eat, drink or smoke while handling product. Wash hands after use.

Storage: Store below 30°C (room temperature).

Other Information: Always read the label before use. See label for further information on handling and storage.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

This SDS describes personal protective measures relating to long term industrial and manufacturing exposure and emergency situations, such as accidents and spills. See product label for personal protective measures during normal use of the marketed product.

Exposure Limits: No exposure limits have been assigned for this product nor for any ingredients.

Engineering Controls: Use only in a well ventilated area. Ensure that the work environment remains clean.



SAFETY DATA SHEET

Title: MAXALAC L.C. INTRAMAMMARY ANTIBIOTIC		Document: SDS-AU053	
		Rev: 1.0	Page: 1 of 7
Status: Current	Issue Date 24-Aug-2019	Effective Date: 24-Aug-2019	Review Date: 02-Jan-2023

Personal Protective Equipment (PPE):

Eye Protection: Protective glasses or goggles are recommended when handling bulk quantities of this product.

Skin Protection: When handling bulk product, prevent skin contact by wearing chemical protective gloves e.g. PVC.

Respiratory Protection: Not required for the normal use of this product.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

Appearance:	White oily paste.	Upper / Lower Flammability Limits:	Not available.
Odour:	Not available.	Vapour Pressure:	Not available.
Odour Threshold:	Not available.	Vapour Density:	Not available.
pH:	3.5 - 5.0	Relative Density / Specific Gravity:	Not available.
Melting Point / Freezing Point:	Not available.	Solubility:	Immiscible in water.
Boiling Point and Boiling Range:	Not available.	Partition Coefficient (n-octanol/water):	Not available.
Flash Point:	Not available.	Auto-Ignition Temperature:	Not available.
Evaporation Rate:	Not available.	Decomposition Temperature:	Not available.
Flammability:	Not available.	Viscosity:	Not available.

Section 10: STABILITY AND REACTIVITY

Reactivity: This product is unlikely to react or polymerise under normal storage conditions.

Chemical Stability: When stored appropriately this product should show no significant degradation within the expiry period shown on the label.

Conditions to Avoid: Extreme temperatures.

Incompatible Materials: Oxidising agents.

Hazardous Decomposition Products: No data available.



SAFETY DATA SHEET

Title: MAXALAC L.C. INTRAMAMMARY ANTIBIOTIC		Document: SDS-AU053	
		Rev: 1.0	Page: 1 of 7
Status: Current	Issue Date 24-Aug-2019	Effective Date: 24-Aug-2019	Review Date: 02-Jan-2023

Section 11: TOXICOLOGICAL INFORMATION

REMARK: Cefuroxime is a cephalosporin antibiotic and the most important adverse reaction is hypersensitivity.

Acute Toxicity:

Ingestion: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be acutely toxic by the oral route.

Cefuroxime sodium: Oral LD₅₀: > 10,000 mg/kg (rat).

Cefuroxime: NOEL: 400 mg/kg/day.

Inhalation: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be acutely toxic by the inhalation route.

Dermal: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be acutely toxic by the dermal route.

Aspiration Hazard: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be an aspiration hazard.

Respiratory Irritation: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be a respiratory irritant.

Skin Corrosion / Irritation: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be a skin irritant.

Serious Eye Damage / Irritation: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be an eye irritant.

Respiratory or Skin Sensitisation: No data for the mixture is available. Based on available data for the ingredients, the mixture is classified as a **Skin sensitizer Category 1**.

Germ Cell Mutagenicity: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be mutagenic.

Carcinogenicity: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be carcinogenic.

Reproductive Toxicity: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be a reproductive toxicant.

Specific Target Organ Toxicity (STOT): Single exposure: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be a specific target organ toxicant after single exposure.

Specific Target Organ Toxicity (STOT): Repeated exposure: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be a specific target organ toxicant after repeat exposure.

Narcotic Effects: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to have any narcotic effects.



SAFETY DATA SHEET

Title: MAXALAC L.C. INTRAMAMMARY ANTIBIOTIC		Document: SDS-AU053	
		Rev: 1.0	Page: 1 of 7
Status: Current	Issue Date 24-Aug-2019	Effective Date: 24-Aug-2019	Review Date: 02-Jan-2023

Section 12: ECOLOGICAL INFORMATION

Ecotoxicity: No data for the mixture is available. Based on available data for the ingredients, the mixture is not considered to be toxic to the environment.

Fish

Cefuroxime sodium: No data.

Crustacea

Cefuroxime sodium: No data.

Algae and other aquatic plants

Cefuroxime sodium: No data.

Ingredient	Persistence: Water/Soil	Persistence: Air	Bioaccumulation	Mobility
Cefuroxime	HIGH	HIGH	LOW (LogKOW = 0.29)	LOW (KOC = 1637)

Section 13: DISPOSAL INFORMATION

Product Disposal: Dispose of product only by using according to label or at an approved landfill.

Container Disposal: Wrap with paper and place in garbage.

Section 14: TRANSPORT INFORMATION

Dangerous Goods Classification: Not considered a Dangerous Good for land, sea and air transport.

Hazchem Code: None specified.

Section 15: REGULATORY INFORMATION

Poisons Schedule: S4

APVMA Registration No: 59528

AICS: All of the significant ingredients in this formulation are compliant with NICNAS regulations.

SUSMP: Cefuroxime is mentioned in the SUSMP.

Section 16: OTHER INFORMATION

Legend:

AICS	Australian Inventory of Chemical Substances.
CAS No.	Chemical Abstracts Service Registry Number.
EPA	Environmental Protection Authority – New Zealand.
GHS	Globally Harmonized System of Classification and Labelling of Chemicals.
Hazchem Code	Emergency action code of numbers and letters that provide information to emergency services especially firefighters.



SAFETY DATA SHEET

Title: MAXALAC L.C. INTRAMAMMARY ANTIBIOTIC		Document: SDS-AU053	
		Rev: 1.0	Page: 1 of 7
Status: Current	Issue Date 24-Aug-2019	Effective Date: 24-Aug-2019	Review Date: 02-Jan-2023

KOC	Soil-Water Partition Coefficient. The ratio of a chemical's concentration that is adsorbed in the soil to the concentration of chemical in solution.
KOW	Octanol Water Partition Coefficient. The ratio of a compound's concentration in a known volume of n-octanol to its concentration in a known volume of water after the octanol and water have reached equilibrium.
NICNAS	National Industrial Chemicals Notification and Assessment Scheme.
NOEL	No-observable-effect-level.
PPE	Personal Protective Equipment.
PVC	Polyvinyl chloride.
SUSMP	Standard for the Uniform Scheduling of Medicines and Poisons.

References:

ChemID Plus

EPA New Zealand Chemical Classification and Information Database (CCID)

HSDB (Hazardous Substances Data Bank)

Revision History:

Date of Revision	Reason
28 November 2017	Updates to section 1, 2, 3, 4, 5, 8, 10, 11, 12, 13 & 15; Updates to Legend and addition of Revision History in Section 16.
2 January 2018	Reclassification to remove classification of Respiratory Sensitizer Category 1 to harmonise with classification made by the New Zealand EPA for this product. Addition of ecological information for cefuroxime in Section 12.

This information is based on data believed by Avet Health Pty Ltd Pty Limited to be accurate at the time of writing but is subject to change without notice. It is given in good faith, but no warranty expressed or implied is made as to its accuracy, completeness otherwise and no assumption of liability from howsoever arising is made by Avet Health Pty Ltd by reason of the provision of this information. Every person dealing with the materials referred to herein do so at his/her own risk absolutely and must make independent determinations of suitability and completeness of information from all sources to ensure their proper use.

END OF SDS